Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dermatology. 2007;215(1):41-4.

Infliximab for the treatment of hidradenitis suppurativa.

Author information

  • 1Department of Dermatology, University Hospital of Puerto Real, University of Cádiz, Cádiz, Spain. fdezvozmediano@dermasur.com

Abstract

INTRODUCTION:

Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective.

OBJECTIVE:

To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms of hidradenitis suppurativa.

DESIGN:

A retrospective study in a group of 6 patients who received treatment with infliximab for hidradenitis suppurativa, in the Dermatology Department of the University Hospital of Puerto Real in the last year. The dose was 5-10 mg/kg at weeks 0, 2 and 6, followed by a maintenance dose every 4 weeks. Subjective and objective efficacy was assessed before and after each treatment session.

RESULTS:

All patients experienced improvement in subjective symptoms after the initial dose. A decrease in exudation, the size and number of lesions and less development of fistulous tracts were observed. The patients were followed up during 6 months. Treatment was generally well tolerated and there was only one mild reaction to the infusion in the form of headache. No patient required treatment discontinuation due to adverse effects.

CONCLUSIONS:

Infliximab was shown to be an effective therapeutic alternative for severe extensive forms of hidradenitis suppurativa when it is used as monotherapy.

2007 S. Karger AG, Basel

PMID:
17587838
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk